Understanding how the immune system responds to SARS-CoV-2
Innate Control of Adaptive Immunity to SARS-CoV-2
This study is looking at how our body's first line of defense, the innate immune system, helps shape the stronger immune response that fights off COVID-19, with the hope that what we learn can lead to better vaccines and help patients recover more effectively.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11090557 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which the innate immune system influences the adaptive immune response to SARS-CoV-2, the virus responsible for COVID-19. By utilizing a specially designed mouse model, the study aims to explore how specific immune signals, such as type I interferon and cGAS signaling, contribute to the development of antibodies against the virus. The findings could provide crucial insights into the immune processes that lead to effective vaccine development and improved patient outcomes. Patients may benefit from this research as it seeks to uncover the fundamental rules of immunity that could inform future vaccine strategies.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals who are at risk of COVID-19 or those interested in understanding immune responses to viral infections.
Not a fit: Patients who are not affected by COVID-19 or do not have a significant interest in vaccine development may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines against SARS-CoV-2 and potentially other coronaviruses.
How similar studies have performed: Other research has shown promise in understanding immune responses to viral infections, but this specific approach to studying SARS-CoV-2 immunity is relatively novel.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Goldman-Israelow, Benjamin — Yale University
- Study coordinator: Goldman-Israelow, Benjamin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.